Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.56 |
| ▸ | DRD3 | P35462 | 3/20 | 0.56 |
| ▸ | DRD4 | P21917 | 1/20 | 0.56 |
| ▸ | HTR1A | P08908 | 3/20 | 0.54 |
| ▸ | HTR2A | P28223 | 2/20 | 0.54 |
| ▸ | HTR7 | P34969 | 1/20 | 0.54 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
| ▸ | SLC2A2 | P11168 | 1/20 | 0.47 |
| ▸ | SLC2A3 | P11169 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.45 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.44 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7497109 | 0.83 | DRD2 (0.59) | DRD2DRD3DRD4HTR1AHTR2A | |
| SCHEMBL10819371 | 0.82 | DRD2 (0.56) | DRD2DRD3DRD4SLC2A1SLC2A2 | |
| SCHEMBL4402731 | 0.81 | DRD4 (0.54) | DRD2DRD3DRD4HTR2AADRA1A | |
| SCHEMBL4401487 | 0.80 | ALDH1A1 (0.50) | DRD2DRD3DRD4HTR1AHTR2A | |
| SCHEMBL29086088 | 0.79 | SLC2A1 (0.52) | DRD2DRD3DRD4HTR1AHTR2A | |
| SCHEMBL30585959 | 0.79 | SLC2A1 (0.52) | DRD2DRD3DRD4HTR1AHTR2A | |
| SCHEMBL9207789 | 0.78 | DRD2 (0.52) | DRD2DRD3DRD4HTR1AHTR2A | |
| SCHEMBL27815937 | 0.77 | CYP1A2 (0.51) | DRD2DRD3DRD4HTR1AHTR2A | |
| SCHEMBL13532641 | 0.77 | HTR1A (0.61) | DRD2DRD3DRD4HTR1AHTR2A | |
| SCHEMBL4404160 | 0.77 | DRD2 (0.75) | DRD2DRD3HTR1AHTR7ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1971600-B1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2013-08-21 | — | — | EP | claimed |
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2009-05-21 | — | — | US | claimed |
| EP-1971600-B1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2013-08-21 | — | — | EP | disclosed |
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2009-05-21 | — | — | US | disclosed |
| EP-1971600-A1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK Holdings Co., Ltd. (KR) | 2008-09-24 | — | — | EP | disclosed |
| WO-2007078113-A1 | ISOXAZOLE DERIVATIVES AND USE THEREOF | SK HOLDINGS CO., LTD. (KR) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | WNT3A, WNT1, WNT3 | DRD2 3882/4885DRD3 3114/4885DRD4 3571/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.